ウェビナー動画：Boehringer Ingelheim社、次世代シーケンス（NGS）によるランダムトランスジーンインテグレーション解析
In this webinar, Dr. Benjamin Lindner from Boehringer Ingelheim presents in-depth analysis of the top 3 production clones at Boehringer Ingelheim using TLA (Targeted Locus Amplification) technology.
This allowed his team to:
- better understand the effects of random transgene integration in CHO cells
- assess performance characteristics by measuring viability and antibody titers
- perform in-depth genetic characterization critical to assessing cell stability
TLA data processed in Genedata Selector® enabled the precise characterization of vector integration sites. Further analysis allowed the identification of sibling clones (derived from a common mother cell) based on identical integration sites. Benjamin also discusses the impact of supertransfection (repeated transfection) on antibody titers and genetic stability.
This talk was given as part of our regular Open Forums on biosafety and cell line development.
Who should watch?
Biopharma and biotech professionals looking to advance rational cell line development by embracing digitalization and innovative enterprise data analysis systems.
